Impact of food intake on the antisecretory effect of low-dose ranitidine and famotidine

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 3, 1999, Pages 407-412

  Netzer, P ^a   Eschenmoser, K ^a   Halter, F ^a   Inauen, W ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; NON PRESCRIPTION DRUG; RANITIDINE; STOMACH SECRETION INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; MEAL; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH PH;

ADULT; ANTI-ULCER AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FAMOTIDINE; FEMALE; FOOD-DRUG INTERACTIONS; GASTRIC ACID; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; RANITIDINE;

EID: 0033055308     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00478.x     Document Type: Article

References (31)

1. 1 Drossmann DA, Li Z, Andruzzi E, Temple RD, Talley NJ. US householder survey functional gastrointestinal disorders-prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38: 1569-80.
2. 2 Tew S, Jamieson GG, Pilowsky I, Myers JC. The illness behavior of patients with gastroesophageal reflux disease with and without endoscopic esophagitis. Dis Esophagus 1997; 10: 9-15.
3. 3 Oster G, Huse DM, Delea TE, Colditz GA, Richter JM. The risk and benefits of an Rx-to-OTC switch. Med Care 1990; 28: 834-52.
4. 2-receptors safe over the counter drugs? Br Med J 1994; 309: 493-4.
5. 2-receptor antagonists. Arch Intern Med 1993; 153: 2415-24.
6. 6 Feldman M. Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid. J Am Med Assoc 1996; 275: 1428-31.
7. 7 Reilly TG, Singh S, Cottrell J, Mann SG, Stauffer L, Walt RP. Low-dose famotidine and ranitidine as single post-prandial doses: a three-period placebo-controlled comparative trial. Aliment Pharmacol Ther 1996; 10: 749-55.
8. 2-receptor antagonist (famotidine). Am J Ther 1995; 2: 304-13.
9. 9 Reilly TG, Mann SG, Panos MZ, Walt RP. Low dose famotidine and cimetidine in single postprandial doses: a placebo controlled comparative study of overnight pH. Gut 1995; 37: 325-8.
10. 10 Grimley CE, Cottrell J, Mann SG, Stauffer L, Nwokolo CU. Nocturnal intragastric acidity after over-the-counter doses of famotidine, ranitidine or placebo. Aliment Pharmacol Ther 1997; 11: 881-5.
11. 11 Grimley CE, Constantinides S, Snell CC, Mills JG, Nwokolo CU. Inhibition of intragastric acidity in healthy subjects dosed with ranitidine 75 mg: a comparative study with cimetidine and placebo. Aliment Pharmacol Ther 1997; 11: 875-9.
12. 2-antagonist treatment. Gastroenterology 1991; 101: 599-606.
13. 13 Grimley CE, West JM, Loft DE, et al. Early and late effects of low-dose famotidine, ranitidine or placebo on pentagastrin-stimulated gastric acid secretion in man. Aliment Pharmacol Ther 1996; 10: 743-7.
14. 14 Johnston DJ, Wormsley KG. The effect of food on ranitidine-induced inhibition of nocturnal gastric secretion. Aliment Pharmacol Ther 1988; 2: 507-11.
15. 15 Berstad A, Rydning A, Kolstad B, Frislid K. Reduction of postprandial gastric acidity and pepsin concentration by ranitidine and antacids in healthy volunteers. Scand J Gastroenterol 1981; 69(Suppl.): 67-73.
16. 16 Hunt RH. The relationship between the control of pH and healing and symptom relief in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9(Suppl. 1): 3-7.
17. 17 Netzer P, Inauen W, Halter F. Standartdiagnostik bei gastroösophagealer Refluxkrankheit (Standard diagnostic in the gastroesophageal reflux disease). Chir Gastroenterol 1997; 13: 98-104.
18. 18 Schindlbeck NE, Ippisch H, Klauser AG, Müller-Lissner SA. Which pH threshold is best in esophageal pH monitoring? Am J Gastroenterol 1991; 86: 1138-41.
19. 19 Berstad A, Holm HA, Kittang E. Experience with antipeptic agents. Scand J Gastroenterol 1979; 14(Suppl. 55): 121-3.
20. 20 Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastrooesophageal disease. Digestion 1992; 51(Suppl. 1): 59-67.
21. 2-receptor antagonist in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9(Suppl. 1): 9-14.
22. 22 Smith JL, Operkun AR, Larkai E, Graham DY. Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology 1989; 96: 683-9.
23. 2-receptor antagonists (ranitidine, famotidine) on intragastric acidity. Aliment Pharmacol Ther 1998; 12: 337-42.
24. 24 Wilder-Smith CH, Gennoni MA, Triller J, Scheurer U, Merki HS. Is a fluoroscopic verification of the electrode position necessary in ambulatory intragastric pH monitoring? Digestion 1992; 52: 1-5.
25. 2-antagonists. Gastroenterology 1985; 88: 1842-51.
26. 26 Netzer P, Hammer B. Indikationen, Resultate und Konsequenzen der 24 Stunden-Oesophagus-pH-Metrie bei 50 konsekutiven Patienten (Indications, results, and consequences of 24-hour esophageal pH monitoring). Schweiz Med Wochenschr 1996: 126 (Suppl. 79): 535-75.
27. 27 Hettmansperger TP. Statistical Inference Based on Ranks. New York: Wiley, 1984.
28. 28 Holm S. A simple sequentially rejective multiple test procedure. Scand Statist 1979; 6: 65-70.
29. 29 Halter F, Huber R, Häcki WH, Varga L, Bachmann C. Effect of food on antacid neutralizing capacity in man. Eur J Clin Invest 1982; 12: 209-17.
30. 30 Mann SG, Murakami A, McCarroll K, Rao AN, Cottrell J, Mehentee J. Low dose famotidine in prevention of sleep disturbance caused by heartburn after an evening meal. Aliment Pharmacol Ther 1995; 9: 395-401.
31. 31 Reilly TG, Grimley CE, Usselmann B, Mann SG, Raskin S, Nwokolo CU. Low-dose famotidine and effervescent cimetidine in healthy subjects: a placebo-controlled overnight pH study. Aliment Pharmacol Ther 1998; 12: 469-74.